Clemens Kratochwil

Clemens Kratochwil has been a pioneer in the clinical application of actinium-225 (Ac-225) PSMA-617 alpha-particle radioligand therapy for advanced prostate cancer, reporting the first clinical results demonstrating dramatic PSA responses in patients who had progressed on Lu-177 beta-particle therapy. His compassionate use experience showed that Ac-225 PSMA-617 achieves complete remissions in some patients with end-stage mCRPC, including those refractory to Lu-177 therapy, attributed to the higher linear energy transfer and shorter range of alpha particles. He has contributed to early-phase clinical development of Ac-225 radioligand conjugates and addressed practical challenges including Ac-225 supply limitations and xerostomia management.